What Stafa Cellular Therapy does

Stafa Cellular Therapy (legal entity StafaCT, Inc.) is a private healthcare software company headquartered in Fremont, California, founded in 2015 as a spin-off from nCoup, where the cellular therapy product team previously operated. The company sells an integrated six-product software platform purpose-built for cellular therapy and bone marrow transplant (BMT) programs at hospitals, medical centers, and specialized cellular therapy labs. The platform manages the full transplant workflow from patient referral through infusion and follow-up, comprising Stafa Clinical (recipient/donor data capture and electronic approvals), Stafa Apheresis (collection process workflow), Stafa Cellular Therapy Lab/CTL (lab automation with configurable protocols and product tracking), Stafa Reporting & Analytics (CIBMTR submission and operational analytics), Stafa ISBT Labeling (ISBT 128 compliant label generation with 2D barcoding), and Stafa Quality & Compliance (a real-time rules engine with an out-of-the-box FACT standards library). Underlying technical components include HL7-based integration with EMRs, patient demographics (ADT), and lab systems; 21 CFR Part 11 compliant electronic signatures and audit trails; and configurable workflows supporting diverse CTL applications.

The company operates a primarily enterprise software revenue model, monetized through quote-based subscription or licensing agreements, with no publicly disclosed pricing. Go-to-market combines direct enterprise field sales (driven by Request Demo CTAs) with an exclusive worldwide distribution partnership with Terumo BCT, which provides global marketing, sales, and support reach into the cell therapy domain. Two secondary technology partnerships with AITHENT and COMAIBA extend the platform's compliance and quality management footprint, including standalone distribution of the Quality & Compliance module through COMAIBA's channel. The addressable customer base is highly specialized, limited to healthcare institutions operating accredited cellular therapy and BMT programs, with no named customers or disclosed customer count in the available data.

Name

Stafa Cellular Therapy

Legal name

StafaCT, Inc.

Website

https://stafa-ct.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

101–250 employees

Short description

Stafa Cellular Therapy provides an integrated six-product software platform for cellular therapy and bone marrow transplant programs, automating workflow, ISBT 128 labeling, and FACT compliance from referral through follow-up for hospital and lab customers.

Ownership category

akta.pro rank

Product category

Healthcare Workflow Software

NAICS

Custom Computer Programming Services (541511), Computer Systems Design and Related Services (54151)

SIC

Services-Computer Programming, Data Processing, Etc. (7370), Services-Health Services (8000)

akta.pro primary industry

Cell Therapy Manufacturing Platforms & Automation (closed systems, bioreactors, fill-finish) (HLAAABAG)

akta.pro secondary industries

Bone Marrow & Stem Cell Transplant (BMT/HSCT) (HLAKAFAI), Lab Data Exchange & Interoperability (HL7/FHIR/LDT Results Delivery) (HLACAMAL)

Keywords

• Cellular therapy software
• Bone marrow transplant software
• Blood and marrow transplant
• Healthcare compliance software
• ISBT 128 labeling

Headquarters

HQ city

Fremont

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Marketing or Sales, Operations

Revenue model

1. Enterprise Software Licenses/Subscriptions: Comprehensive software suite for cellular therapy and bone marrow transplant programs, sold as enterprise software with multiple integrated products covering the entire transplant workflow from referral to infusion and follow-up

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

Stafa Cellular Therapy sells an integrated, workflow-driven enterprise software suite that manages the entire blood and marrow transplant (BMT) and cellular therapy process from referral to infusion and follow-up. The platform automates data collection, generates ISBT 128 compliant labels, integrates with EMR and lab systems via HL7, and provides real-time compliance monitoring against FACT standards, with electronic approvals and audit trails meeting 21 CFR Part 11 requirements.

Product overview

Stafa Cellular Therapy offers a comprehensive, workflow-driven software platform that manages the entire blood and marrow transplant (BMT) and cellular therapy process. The platform consists of six integrated products: Stafa Clinical (recipient and donor workflow management), Stafa Apheresis (collection process management), Stafa Cellular Therapy Lab/CTL (lab automation and product tracking), Stafa Reporting & Analytics (CIBMTR submission and operational analytics), Stafa ISBT Labeling (ISBT 128 compliant label generation), and Stafa Quality & Compliance (regulatory compliance monitoring). These products work together to automate data collection from referral to infusion and follow-up, connecting all cellular therapy-associated departments with real-time quality monitoring and ISBT 128 label generation capabilities.

Differentiator

Problem solved

Functional benefit

Products and services

• Stafa Clinical

Quantifiable outcome

• Reduce paperwork management costs through centralized quality data repository
• +2 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration2 records

Feature8 records

Partnerships

One partnership is on record.

• Terumo BCTflagshipChannel Partner/ Reseller/ DistributorTerumo BCT is StafaCT's exclusive worldwide marketing, sales, and support partner for Apheresis, Cell Therapy, and Transplant products. Terumo BCT provides global distribution reach and deep domain expertise in the cell therapy world. Stafa CT focuses on technology development while Terumo BCT handles go-to-market execution.

Scale indicators2 records

Recent moves5 records

Expansion highlights4 records

Direct peers

• Blood Bank Computer Systems (BBCS): BBCS provides blood bank and transfusion management software to hospital and donor center clients, with overlap to StafaCT in cellular product labeling and compliance. It is a closely comparable niche vendor serving similar regulated workflows.
• HemaTerra: HemaTerra provides software for blood and cell therapy collection and processing workflows, including donor and product management. It competes directly with StafaCT in the apheresis and cellular therapy lab workflow space.
• StemSoft Software (acquired by Haemonetics): StemSoft was the most direct competitor to StafaCT in cell therapy and BMT workflow software before being acquired by Haemonetics. It addressed the same buyer (transplant programs) with comparable apheresis, lab, and clinical modules.

Broad incumbents

• WellSky (formerly Mediware) Blood Bank / Cell Therapy: WellSky offers blood bank and cellular therapy management software historically derived from Mediware products. It targets the same hospital-based blood, marrow, and cell therapy programs that StafaCT serves, but as part of a much broader healthcare software portfolio.
• Haemonetics (Blood Center / Cell Therapy software): Haemonetics, through its acquisition of StemSoft, offers cell therapy and blood center software suites that overlap materially with StafaCT's modules. As a global blood management incumbent, it competes for the same hospital and cell therapy lab accounts.
• Epic Systems (Beaker LIS / Transfusion & Cellular Therapy modules): Epic's Beaker LIS and specialty modules address lab, transfusion, and increasingly cellular therapy workflows within its dominant EHR platform. As hospitals consolidate on Epic, StafaCT faces the risk of being displaced or replaced by Epic-built functionality.
• Oracle Health (Cerner) Transplant & Cell Therapy solutions: Oracle Health, the successor to Cerner, offers transplant and specialty modules within its EHR that overlap with StafaCT's transplant and BMT workflow coverage. It represents a broad incumbent competitor pushing into StafaCT's niche from a much larger installed base.
• Roche (Cell Therapy Software via Vyriad and CellBase partnerships): Roche and its diagnostics arm invest in cell therapy workflow and digital infrastructure tools for advanced therapy manufacturers and treatment centers, putting them in indirect competition with StafaCT's cellular therapy lab platform.

Emerging players

• SCC Soft Computer: SCC Soft Computer offers laboratory information systems and blood bank modules used by hospitals and donor centers. It competes with StafaCT at the lab data and interoperability layer, particularly where general LIS suites overlap with cellular therapy workflows.
• Lonza (Cell & Gene Therapy Manufacturing Software / MODA-ES): Lonza's MODA-ES platform supports cell and gene therapy manufacturing quality and data management, overlapping with StafaCT's Quality & Compliance and CTL modules. It is more focused on manufacturing sponsors but targets adjacent workflow and compliance needs.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Stafa Cellular Therapy